5-fluoropyrimidine has been researched along with Lung Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G | 1 |
1 trial(s) available for 5-fluoropyrimidine and Lung Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Pyridines; Pyrimidines; Stomach Neoplasms; Tegafur; Time Factors | 2004 |